UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.89 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 6.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,241 shares of the company’s stock after selling 2,162 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.07% of Apogee Therapeutics worth $1,894,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Apogee Therapeutics during the 3rd quarter worth about $71,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Apogee Therapeutics by 21.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock worth $94,000 after purchasing an additional 285 shares during the period. Allspring Global Investments Holdings LLC bought a new position in Apogee Therapeutics during the second quarter worth about $143,000. Arizona State Retirement System boosted its holdings in Apogee Therapeutics by 4.5% during the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock valued at $236,000 after purchasing an additional 258 shares in the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of Apogee Therapeutics by 26.3% in the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock valued at $253,000 after purchasing an additional 1,340 shares during the period. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Stock Up 0.4 %

Shares of NASDAQ APGE opened at $44.50 on Monday. Apogee Therapeutics, Inc. has a 12-month low of $20.78 and a 12-month high of $72.29. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -18.39 and a beta of 2.30. The firm’s 50-day simple moving average is $51.43 and its 200 day simple moving average is $48.30.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on APGE shares. Canaccord Genuity Group initiated coverage on Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 target price for the company. Guggenheim reissued a “buy” rating on shares of Apogee Therapeutics in a report on Thursday. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 target price on the stock. Finally, Wedbush increased their target price on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the stock an “outperform” rating in a research report on Monday, December 2nd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $83.88.

Insider Activity

In related news, insider Carl Dambkowski sold 6,665 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $56.26, for a total transaction of $374,972.90. Following the completion of the sale, the insider now directly owns 274,128 shares of the company’s stock, valued at $15,422,441.28. The trade was a 2.37 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Michael Thomas Henderson sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $56.23, for a total transaction of $2,249,200.00. Following the completion of the transaction, the chief executive officer now directly owns 1,354,487 shares in the company, valued at approximately $76,162,804.01. The trade was a 2.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 94,535 shares of company stock valued at $5,133,635 over the last three months. 36.10% of the stock is owned by insiders.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.